Results 31 to 40 of about 75,416 (289)

Mitral regurgitation at the time of left ventricular assist device implantation: Should it be treated or not?Central MessagePerspective

open access: yesJTCVS Open
Objective: Mitral regurgitation may persist or progress after left ventricular assist device implantation. However, whether preexisting mitral regurgitation should be corrected at the time of implantation remains to be determined.
Hiroki Kohno, MD, PhD   +4 more
doaj   +1 more source

Remote Dielectric Sensing to Assess Residual Pulmonary Congestion Following Percutaneous Mitral Valve Repair

open access: yesMedicina, 2022
Background and Objectives: Percutaneous mitral valve repair using a MitraClip system is an established therapeutic strategy to treat severe mitral regurgitation, which is recommended by guidelines in Europe and in the United States, whereas residual ...
Teruhiko Imamura   +3 more
doaj   +1 more source

Association between the proportionality of functional mitral regurgitation and survival after mitral valve operationCentral MessagePerspective

open access: yesJTCVS Open
Objective: The concept of proportionate and disproportionate functional mitral regurgitation suggests that transcatheter edge-to-edge mitral repair may benefit patients with a smaller left ventricle relative to a higher regurgitant burden.
Makoto Mori, MD, PhD   +7 more
doaj   +1 more source

Pathoanatomy of Mitral Regurgitation [PDF]

open access: yesStructural Heart, 2020
The mitral valve is a dynamic, three-dimensional (3D) structure consisting of the mitral annulus, leaflets, tendinous chordae, and papillary muscles.
Ilya Karagodin   +2 more
openaire   +2 more sources

Port-Access Robotic Repair of Barlow Mitral Annular Disjunction and Severe Mitral Valve Regurgitation

open access: yesAnnals of Thoracic Surgery Short Reports
Mitral annular disjunction (MAD) is associated with malignant ventricular arrhythmias and progressive mitral regurgitation. We describe a 35-year-old man with a history of sudden cardiac death who presented with palpitations and recurrent ventricular ...
Shazil Mahmood, MD   +6 more
doaj   +1 more source

Midterm Outcomes of Pediatric Mitral Valvuloplasty for Moderate to Severe Mitral Valve Regurgitation and Associated Risk Factors for Postoperative Deterioration [PDF]

open access: yesTexas Heart Institute Journal
Background: Mitral valvuloplasty is considered the best treatment for pediatric mitral valve regurgitation. The objective of this analysis was to identify risk factors for postoperative mitral valve regurgitation progression and evaluate valvuloplasty ...
Hongyuan Fu, MD   +4 more
doaj   +1 more source

Engineering Strain‐Stiffening Granular Hydrogels for 3D‐Printed Tissue‐Mimicry

open access: yesAdvanced Materials, EarlyView.
A 3D‐printable strain‐stiffening double‐network granular hydrogel (SDGH) enables independent, region‐specific tuning of toe (EToe) and heel (EHeel) moduli through control of microgel packing and network composition. This platform replicates tissue‐like nonlinear mechanics and allows fabrication of high‐fidelity, multilayered aortic valves with ...
Hyeokju Chae   +9 more
wiley   +1 more source

ASSESSMENT OF MITRAL REGURGITATION SEVERITY BY DIFFERENT ECHOCARDIOGRAPHIC METHODS IN COMPARISON WITH LEFT VENTRICLE ANGIOGRAPHY

open access: yesThe Iraqi Journal of Medical Sciences, 2016
Background:Proximal isovelocity surface area method and mitral regurgitatant jet estimation (with its ratio to left atrium) are reliable methods for estimation of mitral regurgitation severity aiding in management strategy, precluding the use of other ...
Rafid B. Altaweel   +1 more
doaj   +4 more sources

Targeted Anti‐IL‐1 Immunomodulatory Therapy in Pediatric Onset PPP1R13L‐Related Arrhythmogenic Cardiomyopathy

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Autosomal recessive loss‐of‐function variants in PPP1R13L cause an ultra‐rare cardiocutaneous syndrome characterized by rapidly progressive arrhythmogenic cardiomyopathy (ACM). PPP1R13L encodes iASPP, which has two potentially overlapping mechanisms driving ACM as both a regulator of NFκB‐mediated inflammation and a binding partner within the ...
Aaron Renberg   +9 more
wiley   +1 more source

Advances in transcatheter mitral and tricuspid therapies

open access: yesBMC Cardiovascular Disorders, 2020
Background While rheumatic mitral stenosis has been effectively treated percutaneously for more than 20 years, mitral and tricuspid regurgitation treatment appear as a contemporary unmet need.
Pavel Overtchouk   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy